LAS VEGAS—A multimodal analgesic regimen consisting of zopiclone, gabapentin and/or celecoxib did not confer any benefits over a standard opioid-based approach in patients following hip arthroscopy, according to the results of a new study.
The investigation, which was presented at the 2023 annual meeting of the American Academy of Orthopaedic Surgeons, found no differences between groups in terms of pain scores, opioid consumption or hospital length of stay (LOS). Nevertheless, the authors